A subject of the invention is a replication-expressing vector. Further, a subject of the invention is a PhoA-His6-polysignal protein TSRGDHELLGGGAAPVGG_10 fusion protein comprising the vector defined above, PhoA-His6-polysaccharide fusion protein MaIE-His6-polysaccharide fusion protein TSRGDHELLGGGAAPVGG_20-40 comprising the vector specified above, His6-c-Myc-WYY-Ubiquitin-polysaccharide fusion protein RGD_10 comprising the vector specified above, His6-c-Myc-WYY-Ubiquitin-polysaccharide fusion protein RGDGG_10 comprising the vector defined above, His6-c-Myc-WYY-Ubiquitin-polysaccharide fusion protein IM_10 comprising the vector defined above, His6-c-Myc-WYY-Ubiquitin-polysaccharide fusion protein RLIDRTNANFLGAAPVGGG_10 comprising the vector defined above. It is also a subject of the invention to use a duplication-expressing vector as defined above for gene expression in Escherichia coli BL21 Star(DE3) cells in vitro, and a composition comprising a purified fusion protein as defined above and a pharmaceutically acceptable carrier or excipient.

Nencki Institute is the co-applicant with University of Gdańsk, Gdańsk University of Technology, Medical University of Gdańsk, MedVentures Sp. z o. o. and ProScience Sp. z o. o. University of Gdańsk is the leader of patent protection and commercialization related activities.

For more information contact Technology Transfer Office.